GlassScriptPhysician profile
Bryan W Burns
NPI 1144273772
$16,055.98
in general payments reported to CMS, 2019-2025
79 companies · $864 in 2025
The $864 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,401 · 2020: $1,881 · 2021: $3,530 · 2022: $3,333 · 2023: $2,564 · 2024: $1,482 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,860 · Education: $50.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,860.00 |
| Education | $50.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,027.39 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,231.50 | 2019-2025 | |
| Lilly USA, LLC | $1,067.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $883.75 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals LP | $878.56 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $803.48 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $741.51 | 2019-2025 | Trintellix |
| Amgen INC. | $727.91 | 2019-2025 | Otezla, Repatha, Evenity |
| Antares Pharma, INC. | $642.89 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Janssen Pharmaceuticals, INC | $478.32 | 2019-2023 | Spravato, Xarelto |
| Vanda Pharmaceuticals INC. | $420.88 | 2019-2024 | Hetlioz, Fanapt |
| Allergan, INC. | $397.88 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $393.35 | 2019-2024 | Livalo, Seglentis |
| Corium, LLC | $324.22 | 2022-2024 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $278.41 | 2019-2025 | Xifaxan, Trulance |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.